Corcept Therapeutics (CORT) Price & Analysis

Compare

1,197 Followers

CORT Stock Chart & Stats

$75.49

$0.08(0.16%)

At close: Jan 08 4:00 PM EST

$75.49

$0.08(0.16%)

Day’s Range― - ―

52-Week Range$49.00 - $117.33

Previous CloseN/A

Volume78.39K

Average Volume (3M)879.48K

Market Cap

$7.75B

Enterprise Value$9.51B

Total Cash (Recent Filing)$421.68M

Total Debt (Recent Filing)$6.36M

Price to Earnings (P/E)84.2

Beta0.51

Next Earnings

Feb 18, 2026

EPS Estimate

0.33

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.16

Shares Outstanding105,188,220

10 Day Avg. Volume730,716

30 Day Avg. Volume879,481

Financial Highlights & Ratios

PEG Ratio1.15

Price to Book (P/B)7.65

Price to Sales (P/S)7.71

P/FCF Ratio26.55

Enterprise Value/Market Cap1.23

Enterprise Value/Revenue12.83

Enterprise Value/Gross Profit13.07

Enterprise Value/Ebitda131.25

Forecast

1Y Price Target

$135.33

Price Target Upside79.27% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering4

EPS Forecast (FY)0.97

Revenue Forecast (FY)$851.60M

Bulls Say, Bears Say

Bulls Say

Financial StabilityCorcept reported cash and cash equivalents of $421.0M, which is believed to be sufficient to fund operations for the foreseeable future.

Market ExpansionCorcept's oncology commercial infrastructure is being expanded to include the EU, suggesting growth opportunities in international markets.

Product Approval And CommercializationThere is high confidence in the potential approval and commercialization of relacorilant for Cushing’s and platinum-resistant ovarian cancer.

Bears Say

Distribution ChallengesThe departure of Optime Care, the exclusive distributor for Korlym, has delayed Corcept's strategy to have at least two pharmacies operational, affecting near-term sales projections.

Earnings HeadwindsThere may be near-term earnings headwinds, including potential for a downward revision of 2025 revenue guidance.

Revenue Guidance RevisionManagement has once again lowered their revenue guidance, currently revising it to a $50M decline.

Corcept Therapeutics News

Corcept Therapeutics reports Q3 EPS 16c, consensus 14c

Reports Q3 revenue $207.6M, consensus $218.5M. “The third quarter marked another period of robust growth in our hypercortisolism...

7d ago

CORT

Corcept submits relacorilant marketing authorization application to EMA

Corcept Therapeutics (CORT) has submitted a marketing authorization application to the European Medicines Agency for relacorilant to treat...

29d ago

CORT

Corcept Therapeutics’ Earnings Call Highlights Growth Amid Challenges

Corcept Therapeutics (($CORT)) has held its Q3 earnings call. Read on for the main highlights of the call....

6d ago

CORT

Corcept Therapeutics Reports Q3 Growth and Expands Oncology Programs

Corcept Therapeutics ( ($CORT) ) has released its Q3 earnings. Here is a breakdown of the information Corcept...

7d ago

CORT

Corcept Therapeutics Reports Q3 2025 Revenue Growth

The latest update is out from Corcept Therapeutics ( ($CORT) ). On November 4, 2025, Corcept Therapeutics announced...

7d ago

CORT

CORT Upcoming Earnings Report: What to Expect?

Corcept Therapeutics (CORT) is scheduled to report 3rd quarter earnings on 10/29/2025. Regarding Q3 estimates, Wall Street analysts...

16d ago

CORT

Promising Potential of Corcept Therapeutics’ Relacorilant in Ovarian Cancer Treatment Drives Buy Rating

H.C. Wainwright analyst Swayampakula Ramakanth has reiterated their bullish stance on CORT stock, giving a Buy rating today....

23d ago

CORT

Corcept Therapeutics Ends Distribution Agreement with Optime

Corcept Therapeutics ( ($CORT) ) has issued an update. On October 10, 2025, Corcept Therapeutics announced the termination...

29d ago

CORT

Corcept Therapeutics falls -13.3%

Corcept Therapeutics (CORT) is down -13.3%, or -$11.79 to $76.57. Published first on TheFly – the ultimate source...

1M ago

CORT

H.C. Wainwright says buy Corcept on weakness after Optime exit

H.C. Wainwright analyst Swayampakula Ramakanth notes that specialty pharmacy Curant Rare announced on October 1 that it had...

1M ago

CORT

Corcept lower after Optime Care terminates distributor agreement for Korlym

Shares of Corcept Therapeutics (CORT) are lower in Friday morning trading after Optime Care announced on Thursday that...

1M ago

CORT

Corcept Therapeutics falls -15.0%

Corcept Therapeutics (CORT) is down -15.0%, or -$13.26 to $75.11. Published first on TheFly – the ultimate source...

1M ago

CORT

Corcept Therapeutics Board Member Resigns, Continues as Consultant

An announcement from Corcept Therapeutics ( ($CORT) ) is now available. On October 10, 2025, Gillian Cannon, Ph.D.,...

1M ago

CORT

Corcept Therapeutics management to meet with Truist

Meeting to be held in Chicago on October 1 and in Milwaukee on October 2 hosted by Truist....

1M ago

CORT

CORT FAQ

What was Corcept Therapeutics Inc.’s price range in the past 12 months?

Corcept Therapeutics Inc. lowest stock price was $49.00 and its highest was $117.33 in the past 12 months.

What is Corcept Therapeutics Inc.’s market cap?

Corcept Therapeutics Inc.’s market cap is $7.75B.

When is Corcept Therapeutics Inc.’s upcoming earnings report date?

Corcept Therapeutics Inc.’s upcoming earnings report date is Feb 18, 2026 which is in 98 days.

How were Corcept Therapeutics Inc.’s earnings last quarter?

Corcept Therapeutics Inc. released its earnings results on Nov 04, 2025. The company reported $0.16 earnings per share for the quarter, missing the consensus estimate of $0.164 by -$0.004.

Is Corcept Therapeutics Inc. overvalued?

According to Wall Street analysts Corcept Therapeutics Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Corcept Therapeutics Inc. pay dividends?

Corcept Therapeutics Inc. does not currently pay dividends.

What is Corcept Therapeutics Inc.’s EPS estimate?

Corcept Therapeutics Inc.’s EPS estimate is 0.33.

How many shares outstanding does Corcept Therapeutics Inc. have?

Corcept Therapeutics Inc. has 105,188,220 shares outstanding.

What happened to Corcept Therapeutics Inc.’s price movement after its last earnings report?

Corcept Therapeutics Inc. reported an EPS of $0.16 in its last earnings report, missing expectations of $0.164. Following the earnings report the stock price went up 7.806%.

Which hedge fund is a major shareholder of Corcept Therapeutics Inc.?

Currently, no hedge funds are holding shares in CORT

Corcept Therapeutics Stock Smart Score

Outperform

Fundamentals

Return on Equity

16.47%

Trailing 12-Months

Asset Growth

5.02%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Corcept Therapeutics Inc.

Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with advanced ovarian tumors, as well as for the treatment of cortisol excess. The company is also developing selective cortisol modulator to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain and other disorders; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated was incorporated in 1998 and is headquartered in Menlo Park, California.

Corcept Therapeutics (CORT) Earnings & Revenues

Historic Earnings Reports

CORT Earnings Call

Q3 2025

0:00 / 0:00

Earnings Call Sentiment|Neutral

The earnings call highlighted strong revenue growth and a robust pipeline, particularly in hypercortisolism and oncology. However, challenges such as a significant decline in net income and unresolved patent litigation present concerns.View all CORT earnings summaries

CORT Stock 12 Month Forecast

Average Price Target

$135.33

▲(79.27% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"46":"$46","71":"$71","96":"$96","121":"$121","146":"$146"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":145,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$145.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":135.33,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$135.33</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":121,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$121.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[46,71,96,121,146],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,73.47,78.9723076923077,84.47461538461539,89.97692307692307,95.47923076923077,100.98153846153846,106.48384615384614,111.98615384615384,117.48846153846154,122.99076923076923,128.49307692307693,133.9953846153846,139.49769230769232,{"y":145,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,73.47,78.22846153846154,82.98692307692308,87.74538461538462,92.50384615384615,97.2623076923077,102.02076923076925,106.77923076923078,111.53769230769231,116.29615384615386,121.0546153846154,125.81307692307693,130.57153846153847,{"y":135.33,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,73.47,77.12615384615384,80.7823076923077,84.43846153846154,88.09461538461538,91.75076923076924,95.40692307692308,99.06307692307692,102.71923076923076,106.37538461538462,110.03153846153846,113.68769230769232,117.34384615384616,{"y":121,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":47.62,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":59.21,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50.39,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":66.92,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":60.58,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":91.93,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":71.48,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":71.68,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":69.31,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":69,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":71.38,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":84.25,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":73.47,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >